» Articles » PMID: 36778023

PAnno: A Pharmacogenomics Annotation Tool for Clinical Genomic Testing

Overview
Journal Front Pharmacol
Date 2023 Feb 13
PMID 36778023
Authors
Affiliations
Soon will be listed here.
Abstract

Next-generation sequencing (NGS) technologies have been widely used in clinical genomic testing for drug response phenotypes. However, the inherent limitations of short reads make accurate inference of diplotypes still challenging, which may reduce the effectiveness of genotype-guided drug therapy. An automated Pharmacogenomics Annotation tool (PAnno) was implemented, which reports prescribing recommendations and phenotypes by parsing the germline variant call format (VCF) file from NGS and the population to which the individual belongs. A ranking model dedicated to inferring diplotypes, developed based on the allele (haplotype) definition and population allele frequency, was introduced in PAnno. The predictive performance was validated in comparison with four similar tools using the consensus diplotype data of the Genetic Testing Reference Materials Coordination Program (GeT-RM) as ground truth. An annotation method was proposed to summarize prescribing recommendations and classify drugs into avoid use, use with caution, and routine use, following the recommendations of the Clinical Pharmacogenetics Implementation Consortium (CPIC), etc. It further predicts phenotypes of specific drugs in terms of toxicity, dosage, efficacy, and metabolism by integrating the high-confidence clinical annotations in the Pharmacogenomics Knowledgebase (PharmGKB). PAnno is available at https://github.com/PreMedKB/PAnno. PAnno provides an end-to-end clinical pharmacogenomics decision support solution by resolving, annotating, and reporting germline variants.

Citing Articles

Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.

Deserranno K, Tilleman L, Rubben K, Deforce D, Van Nieuwerburgh F Front Pharmacol. 2023; 14:1286764.

PMID: 38026945 PMC: 10679755. DOI: 10.3389/fphar.2023.1286764.

References
1.
Shaw K, Amstutz U, Kim R, Lesko L, Turgeon J, Michaud V . Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit. 2015; 37(4):428-36. DOI: 10.1097/FTD.0000000000000192. View

2.
Ashley E . Towards precision medicine. Nat Rev Genet. 2016; 17(9):507-22. DOI: 10.1038/nrg.2016.86. View

3.
Klein K, Tremmel R, Winter S, Fehr S, Battke F, Scheurenbrand T . A New Panel-Based Next-Generation Sequencing Method for ADME Genes Reveals Novel Associations of Common and Rare Variants With Expression in a Human Liver Cohort. Front Genet. 2019; 10:7. PMC: 6365429. DOI: 10.3389/fgene.2019.00007. View

4.
Lee S, Wheeler M, Patterson K, McGee S, Dalton R, Woodahl E . Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet Med. 2018; 21(2):361-372. PMC: 6281872. DOI: 10.1038/s41436-018-0054-0. View

5.
Sangkuhl K, Whirl-Carrillo M, Whaley R, Woon M, Lavertu A, Altman R . Pharmacogenomics Clinical Annotation Tool (PharmCAT). Clin Pharmacol Ther. 2019; 107(1):203-210. PMC: 6977333. DOI: 10.1002/cpt.1568. View